Carbamazepine toxicity (diplopia, ataxia, drowsiness)
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Antiepileptic
Also known as Tegretol, Carbatrol, Epitol, CBZ

KDIGO 2024 + manufacturer label
170 branded formulations. Look up specific brands in the Drugs workspace.
Jan Aushadhi — generic available at GoI pharmacies
Carbamazepine primarily acts by stabilizing the inactivated state of voltage-gated sodium channels in neuronal membranes, thereby inhibiting repetitive firing of action potentials. This reduces the propagation of abnormal electrical impulses in the brain. It may also affect calcium channels and enhance central noradrenergic and serotonergic transmission.
Category D — neural tube defects; folate 5 mg pre-conception
Carbamazepine is excreted into breast milk. The American Academy of Pediatrics considers it
Carbamazepine toxicity (diplopia, ataxia, drowsiness)
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Reduced chloramphenicol efficacy
Avoid concurrent use or increase dose with monitoring
Source: KDT 7e · p949
Carbamazepine toxicity (diplopia, ataxia, drowsiness).
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Carbamazepine toxicity (diplopia, ataxia, drowsiness)
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Contraceptive failure
Advise alternative or higher-dose contraception
Source: KDT 7e · p949
Sub-therapeutic doxycycline levels; treatment failure.
Avoid concurrent use or increase dose
Source: KDT 7e · p949
Carbamazepine toxicity (diplopia, ataxia, drowsiness).
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Carbamazepine toxicity (diplopia, ataxia, drowsiness).
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Loss of glycemic control; hyperglycemia.
Increase sulfonylurea dose or switch to non-interacting agent
Source: KDT 7e · p949
Loss of glycemic control; hyperglycemia.
Increase sulfonylurea dose or switch to non-interacting agent
Source: KDT 7e · p949
Loss of glycemic control; hyperglycemia.
Increase sulfonylurea dose or switch to non-interacting agent
Source: KDT 7e · p949
Loss of glycemic control; hyperglycemia.
Increase sulfonylurea dose or switch to non-interacting agent
Source: KDT 7e · p949
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, Katzung·Verified: 2026-05-16 · House clinical team·Cockpit curated: 2026-05-16